{site_meta && site_meta.display_name} Logo

Reportable

Cut through the daily deluge of information from news, social media and scientific literature to better communicate to your audiences, monitor and measure your business reputation and keep a close eye on your competition.

RSS Feed for Reportable

UGI System Upgrades Set to Begin in Quakertown

July 25, 2025 — FOR IMMEDIATE RELEASE Release Date: July 25, 2025 UGI Utilities, Inc. is scheduled to begin a natural gas main replacement project on Friday, August 1, 2025, in Quakertown.

SERI’s eSummit Unveils 2025 Agenda and First Speakers

July 16, 2025 — For Immediate Release: Washington DC, USA – July 16, 2025 SERI is pleased to announce the release of the agenda and first speakers for eSummit 2025, taking place September 8-11 at the Renaissance Minneapolis Hotel, The Depot. This year's program features dozens of sessions and opportunities to learn and connect with executives and innovators from leading technology companies, recyclers, policymakers, and sustainability advocates to accelerate the transition to a circular economy for electronics.

SPARC Health Announces Rebrand, Celebrates Inaugural Cohort Successes, and Invites Community to Upcoming Startup Huddle

July 2, 2025 — SALT LAKE CITY, UT – July 2, 2025 – SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, and in partnership with the Governor's Office of Economic Opportunity (GOEO), announced today its official rebrand from the Utah Healthcare Innovation Network. This strategic change allows SPARC Health to more holistically capture its mission and vision, adopting a name that is both friendlier and more reflective of its core purpose: a “Startup Platform for Advice, Resources, and Community.

FELIQS Announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

July 1, 2025 — Fukuoka, Japan/New York, United States – July 1st 2025 – FELIQS Corporation (“FELIQS”), a biotechnology company developing first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases, today announced the successful completion of a $9 million Series A funding round, co-led by a major American pharmaceutical company and Beyond Next Ventures Inc. , with additional participation from, Japan Science and Technology Agency and existing investors, Mitsubishi UFJ Capital Co.

InFlectis BioScience Announces Publication of Groundbreaking Study on IFB-088’s Therapeutic Potential in ALS in Life Science Alliance

July 1, 2025 — Nantes, France – July 2nd, 2025 – InFlectis BioScience, a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, is proud to announce the acceptance of its latest research article titled “Sephin1 reduces TDP-43 cytoplasmic mislocalization and improves motor neuron survival in ALS models” for publication in the peer-reviewed journal Life Science Alliance, effective July 1, 2025. This study, conducted in collaboration with leading academic and clinical research institutions across Europe, provides compelling preclinical evidence that IFB-088 (also known as Sephin1 or Icerguastat), a modulator of the Unfolded Protein Response (UPR), significantly reduces the cytoplasmic mislocalization of TDP-43 - a pathological hallmark in 97% of amyotrophic lateral sclerosis (ALS) cases – and decreases abnormal RNA splicing associated with TDP-43 nuclear loss of function.